Type of Immunodeficiency, Treatment and Outcomes of Serious BCG Vaccine Complications: A 15 Year Survey

authors:

avatar Samileh Noorbakhsh 1 , avatar Ahmad Siadati 2 , avatar Setareh Mamishi 2 , avatar Lida Fereidoni 2 , avatar Jalil Kooh Paiezadeh 2

Assistant Professor of Pediatric Infectious Disease, Research center of pediatric infectious diseases, Iran University of Medical Sciences, 9121823797
Professor of Pediatric Infectious Disease, Research center of pediatric infectious diseases, Central Children Hospital. Tehran University of Medical Sciences
Warning: No corresponding author defined!
Journal of Comprehensive Pediatrics: Vol.1, issue 2; 43-47
article type: Research Article
received: January 1, 2007
accepted: January 1, 2007

how to cite: Noorbakhsh S, Siadati A, Mamishi S, Fereidoni L, Kooh Paiezadeh J. Type of Immunodeficiency, Treatment and Outcomes of Serious BCG Vaccine Complications: A 15 Year Survey. J Compr Ped. 2007;1(2): 43-47. 

Abstract

Background:To describe the immunologic characteristics and outcomes of the patients with serious BCG complication in a 15- year survey.
Materials and Methods: A descriptive and retrospective study was performed in 2 referral pediatric infectious wards of central Children Hospital, and Rasool Akram Hospital Tehran, Iran between 1989 and 2004.
Results: We studied 76 patients (72% male and 28% female) with serious BCG complications. mean age of 14.41± 1.43 months the results were follows:severe combined immunodeficiency 15.7 % of cases Leukopenia 1.4%; lymphopenia in 2.8%; cell mediated immunodeficiency in 26.3 %, chronic granulomatous disease in 11.2%, common variable immunodeficiency 6.5 %; NK cell deficiency in 5.2%; isolated CD4 deficiency in 5.1 %; hyper IgM syndrome in 1.4 %, mild abnormality in nitroblue tetrazolium (NBT) test 4.2 %;mild hypogammaglobulinemia in 4.2 % and idiopathic disseminated BCG infection in 15.7% of patients.Nineteen patients died due to progressive disseminated mycobacterial infections.
Conclusion: N.k cell deficiency has yet reported as a risk factor for progression and complication of BCG infection. we suggest combination therapy with IFN-? and chemotherapy in all cases of" idiopathic disseminated BCG infections.

Full Text

Full text is available in PDF